IBM: Fairly Valued After Mainframe Plunge; Software Strength Provides Cushion

What happened

IBM's stock fell sharply after second-quarter 2026 results showed a 42% decline in mainframe sales, but the company's software segment now accounts for 45% of revenue and 80% recurring, providing a growth offset. A new Seeking Alpha article rates IBM a cautious Buy, arguing the stock is fairly valued after the drop and highlighting the durable expansion of Red Hat and automation within software. The DeepValue master report maintains a WAIT rating with an attractive entry of $205, as current levels do not offer sufficient upside while consulting remains flat and peers convert AI demand faster. The article notes that IBM's acquisition-driven hybrid and multi-cloud software strategy is compelling but warns that high purchase multiples leave little margin for execution error. Overall, the new coverage reinforces the existing thesis that software strength is real, but execution risks and valuation keep the stock from being a compelling buy at this time.

Implication

Investors should maintain a cautious stance on IBM as the stock currently trades near fair value, with limited margin of safety. The software segment's recurring revenue and growth in Red Hat offer stability, but the sharp decline in mainframe sales and flat consulting highlight transition risks. High acquisition multiples increase execution risk, making the stock vulnerable to any slip in integration or growth. The next few quarters will be critical to see if delayed deals close and AI signings convert into recognized revenue. Until clearer evidence of consulting reacceleration and sustained software growth emerges, the stock is better suited as a hold rather than an aggressive buy.

Thesis delta

The new article slightly upgrades IBM to a cautious Buy, but this does not materially alter the master report's WAIT stance, as the stock remains above its attractive entry of $205. The article reinforces the core thesis that software growth is durable, yet it also underscores the same execution risks from high acquisition multiples and slow consulting conversion. No shift in valuation or catalysts is introduced; the thesis remains wait-and-see until clearer evidence of AI deal conversion emerges.